Cymbiotics Biopharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 19-12-2024
- Paid Up Capital ₹ 0.12 M
as on 19-12-2024
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.50 Cr
as on 19-12-2024
- Revenue 89.50%
(FY 2022)
- Profit 695.44%
(FY 2022)
- Ebitda 7022.29%
(FY 2022)
- Net Worth 79.25%
(FY 2022)
- Total Assets 17.47%
(FY 2022)
About Cymbiotics Biopharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.12 M.
The company has closed loans amounting to ₹2.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pooja Bhartur and Kabir Bhartur serve as directors at the Company.
- CIN/LLPIN
U73100KA2007PTC042586
- Company No.
042586
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Cymbiotics Biopharma Private Limited offer?
Cymbiotics Biopharma Private Limited offers a wide range of products and services, including Dermatology Treatment Services, Medical Treatment Services, Diabetes Care, Cosmetics, Skin Care Cosmetics.
Who are the key members and board of directors at Cymbiotics Biopharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kabir Bhartur  | Director | 25-Mar-2023 | Current |
| Pooja Bhartur | Director | 15-Mar-2021 | Current |
Financial Performance of Cymbiotics Biopharma.
Cymbiotics Biopharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 89.5% increase. The company also saw a substantial improvement in profitability, with a 695.44% increase in profit. The company's net worth Soared by an impressive increase of 79.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cymbiotics Biopharma?
In 2021, Cymbiotics Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 05 Mar 2010 | ₹2.50 Cr | Satisfied |
How Many Employees Work at Cymbiotics Biopharma?
Cymbiotics Biopharma has a workforce of 20 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cymbiotics Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cymbiotics Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
